Samiei S, Simons JM, Engelen SME, et al. - Researchers conducted a systematic review and meta-analysis with the aim to determine the rates of axillary pathologic complete response (pCR) for different breast cancer subtypes in patients with initially clinically node-positive breast cancer. Inclusion of 33 unique studies with 57,531 unique patients was done. Findings showed the highest axillary pCR rate (60%) in correlation with the hormone receptor (HR)–negative/ERBB2-positive subtype. The following axillary pCR rates were recorded for the remaining subtypes in decreasing order: 59% for ERBB2-positive, 48% for triple-negative, 45% for HR-positive/ERBB2-positive, 35% for luminal B, 18% for HR-positive/ERBB2-negative, and 13% for luminal A breast cancer. In light of these data, axillary treatment response can be estimated in the neoadjuvant setting and thus selection of patients for more or less invasive axillary procedures can be done.